Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Net Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Net Income for 8 consecutive years, with -$20.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 1.18% to -$20.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$86.0 million, a 29354.79% decrease, with the full-year FY2023 number at -$18.8 million, up 51.48% from a year prior.
  • Net Income was -$20.0 million for Q3 2025 at Precision Biosciences, up from -$21.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $25.4 million in Q2 2024 to a low of -$30.7 million in Q4 2021.
  • A 5-year average of -$9.9 million and a median of -$11.6 million in 2021 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 387.07% in 2024; the steepest drop was 731.66% in 2024.
  • Precision Biosciences' Net Income stood at -$30.7 million in 2021, then skyrocketed by 161.93% to $19.0 million in 2022, then plummeted by 115.01% to -$2.9 million in 2023, then plummeted by 731.66% to -$23.7 million in 2024, then increased by 15.76% to -$20.0 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Net Income are -$20.0 million (Q3 2025), -$21.1 million (Q2 2025), and -$21.1 million (Q1 2025).